from rnainews.com:
As part of its bid to find a partner for an investigational RNAi-based therapy for brain cancer that has already been tested in humans, Senetek has begun taking steps to have the treatment examined in patients at new clinical sites, a company official told RNAi News this week.
As part of its bid to find a partner for an investigational RNAi-based therapy for brain cancer that has already been tested in humans, Senetek has begun taking steps to have the treatment examined in patients at new clinical sites, a company official told RNAi News this week.
However, the company may find itself fighting an uphill battle in looking for a partner given an apparent absence of any animal data on the drug and an ever-growing concern over the possibility that certain RNAi molecules may trigger unintended immune stimulation.
In fact, one RNAi insider familiar with the drug expressed concerns that it may not be working through an RNAi mechanism at all — an issue that has joined delivery as a major hurdle facing RNAi therapeutics (see RNAi News, 9/4/2008).
Posts
No comments:
Post a Comment